Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
3SBio ( (HK:1530) ) has provided an announcement.
3SBio reported its interim financial results for the first half of 2025, showing a slight decrease in revenue by 0.8% to RMB4,355.5 million compared to the same period in 2024. Despite this, the company achieved a significant increase in net profit attributable to owners by 24.6% to RMB1,358.2 million, driven by other income and gains, and a reduction in finance costs. The results indicate a strong operational performance despite a challenging market environment, with implications for improved profitability and stakeholder confidence.
The most recent analyst rating on (HK:1530) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
3SBio is a biopharmaceutical company based in the Cayman Islands, focusing on the development, production, and sale of pharmaceuticals. The company is involved in the biotechnology industry, primarily offering products related to the treatment of autoimmune diseases, oncology, nephrology, and dermatology.
Average Trading Volume: 50,583,214
Technical Sentiment Signal: Buy
Current Market Cap: HK$67.23B
See more data about 1530 stock on TipRanks’ Stock Analysis page.